Dialysis News and Research

Latest Dialysis News and Research

Denver-based dialysis operator is target of federal probe

DaVita Inc., which is the biggest operator of dialysis clinics in the nation, announced that it is the subject of a government probe into payments for drugs it used in the N.Y. Medicaid program.

27 Oct 2011

FDA's ODAC to review Affymax peginesatide NDA for treatment of CKD-associated anemia

Affymax, Inc. today announced that the U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) will review the New Drug Application (NDA) for peginesatide proposed for the treatment of anemia associated with chronic kidney disease (CKD) in adult patients on dialysis on December 7, 2011 during the afternoon session.

24 Oct 2011

Women can have successful pregnancy after kidney transplantation

A new study recently published in the American Journal of Transplantation reveals that the ability to successfully carry a pregnancy after kidney transplantation is very high, with 73.5% live birth rates.

21 Oct 2011

Data from Concert Pharmaceuticals' CTP-499 study to be presented at ASN Kidney Week 2011

Concert Pharmaceuticals, Inc. today announced that three abstracts relating to CTP-499, its clinical candidate for the potential treatment of diabetic nephropathy, have been accepted for poster presentations at the American Society of Nephrology's (ASN) Kidney Week 2011.

19 Oct 2011

African-Americans donate exclusively to family members for living kidney transplants

Family matters, especially when it comes to African-Americans and living kidney donation. In a study conducted at Wake Forest Baptist Medical Center, researchers found that African-Americans donate almost exclusively to family members for living kidney transplants, as compared to Caucasians.

19 Oct 2011

Electron-beam sterilized dialysis membrane may increase risk of thrombocytopenia

Patients who had undergone hemodialysis using dialyzers that had been sterilized with the use of electron beams were more likely to develop thrombocytopenia, according to a study in the October 19 issue of JAMA.

19 Oct 2011

Viewpoints: CLASS decision ends fear of government bailout; the strengths and failings of U.S. health care

The problem, as numerous experts warned at the time, was whether the program could be run, as the law required, in a way that made it financially solvent for at least 75 years. The difficulty with the CLASS Act was ensuring that premiums could be set low enough to attract widespread participation but high enough to pay tbenefits. The risk was that the program would attract the sickest participants, who thought they might need its protections, and thereby drive premium prices ever higher in a spiral of dysfunctionhe promised.

19 Oct 2011

New research on link between APOL1 gene variants and kidney disease in African Americans

Compared to European Americans, African Americans are four to five times more likely to develop kidney failure. Also, family members of African Americans with kidney failure have an increased risk of developing kidney failure, which suggests that genetics may play a role in this skewed risk between races.

15 Oct 2011

FDA approves PLC's U.S. pivotal trial of RenalGuard to prevent Contrast-Induced Nephropathy

PLC Systems Inc., a company focused on innovative medical device technologies, announced today that it has received final approval from the U.S. Food and Drug Administration to commence its U.S. pivotal trial to study the efficacy of the Company's RenalGuard Therapy and RenalGuard System in the prevention of Contrast-Induced Nephropathy.

14 Oct 2011

FDA grant to foster development of novel pediatric medical devices

The U.S. Food and Drug Administration (FDA) has awarded the Georgia Institute of Technology, Children's Healthcare of Atlanta, Emory University and Saint Joseph's Translational Research Institute (SJTRI) a two-year, $1.8 million grant to foster the development of medical devices focused on the special needs of children.

13 Oct 2011

Time trends in initiation of chronic dialysis in the U.S.

It has become increasingly clear that patients in the United States are starting dialysis at higher and higher levels of kidney function. A team of researchers, led by Dr. Ann O'Hare, University of Washington associate professor of medicine and affiliate investigator at Group Health Research Institute, set out recently to find out what this means for patients, and how much earlier patients are starting dialysis compared with past practices.

12 Oct 2011

Takeda, Affymax announce data from multiple studies of peginesatide on anemia

Affymax, Inc. and Takeda Pharmaceuticals Global Research & Development Center, Inc., U.S., today announced data from multiple studies of peginesatide have been accepted for presentation at the American Society of Nephrology (ASN) Kidney Week 2011 taking place November 8-13, 2011 in Philadelphia, Pa.

11 Oct 2011

Merck receives FDA approval for JUVISYNC to treat type 2 diabetes

Merck, known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has approved JUVISYNC(sitagliptin and simvastatin), a new treatment for type 2 diabetes that combines the glucose-lowering medication sitagliptin, the active component of JANUVIA (sitagliptin), with the cholesterol-lowering medication ZOCOR.

10 Oct 2011

Health Canada approves Trajenta (linagliptin) for type 2 diabetes

Boehringer Ingelheim Canada and Eli Lilly Canada today announced that Health Canada has approved Trajenta (linagliptin), a new oral therapy to improve glycemic control in Canadian adults with type 2 diabetes.

3 Oct 2011

Bristol-Myers to present abstracts on research in liver disease at The Liver Meeting 2011

Bristol-Myers Squibb Company announced today that 22 abstracts on the Company's research in liver disease have been accepted for presentation at The Liver Meeting 2011, the 62nd annual meeting of the American Association for the Study of Liver Diseases, in San Francisco, November 4 - 8.

1 Oct 2011

Dialysis patients with kidney failure more likely to develop serious complications from flu

For most people, the flu is a temporary setback that makes them feel under the weather for a week or two. For dialysis patients with kidney failure, however, the flu is a serious health threat that can lead to pneumonia and other life-threatening complications.

1 Oct 2011

Alexion receives FDA approval for Soliris to treat atypical Hemolytic Uremic Syndrome

The U.S. Food and Drug Administration today approved Soliris (eculizumab) to treat patients with atypical Hemolytic Uremic Syndrome (aHUS), a rare and chronic blood disease that can lead to kidney (renal) failure and is also associated with increased risk of death and stroke.

26 Sep 2011

EMA CHMP adopts positive opinion for Soliris to treat atypical hemolytic uremic syndrome

Alexion Pharmaceuticals, Inc. today announced that the European Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending that the therapeutic indication for Soliris® (eculizumab) be extended to include the treatment of pediatric and adult patients with atypical hemolytic uremic syndrome (aHUS) in Europe.

23 Sep 2011

E.U. CHMP issues positive opinion for use of Celgene's REVLIMID/dexamethasone MM drug

Celgene International Sàrl was notified today that the E.U. Committee for Medicinal Products for Human Use (CHMP), on behalf of the European Medicines Agency (EMA) has concluded an Article 20 review of REVLIMID and issued a positive opinion for the use of REVLIMID in combination with dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.

23 Sep 2011

NYT: Ethics probe involves kidney transplant center, Rep. Berkley

In 2008 Ms. Berkley helped lead an effort to block a move by federal regulators to close Nevada's only kidney transplant center, which her husband's medical practice helps run under a $738,000-a-year contract. She also successfully pushed regulators, as recently as March, to reverse a plan to cut Medicare reimbursement to dialysis centers, including the dozen her husband's medical practice owns.

23 Sep 2011

Dialysis News and Research

Latest Dialysis News and Research

Denver-based dialysis operator is target of federal probe

FDA's ODAC to review Affymax peginesatide NDA for treatment of CKD-associated anemia

Women can have successful pregnancy after kidney transplantation

Data from Concert Pharmaceuticals' CTP-499 study to be presented at ASN Kidney Week 2011

African-Americans donate exclusively to family members for living kidney transplants

Electron-beam sterilized dialysis membrane may increase risk of thrombocytopenia

Viewpoints: CLASS decision ends fear of government bailout; the strengths and failings of U.S. health care

New research on link between APOL1 gene variants and kidney disease in African Americans

FDA approves PLC's U.S. pivotal trial of RenalGuard to prevent Contrast-Induced Nephropathy

FDA grant to foster development of novel pediatric medical devices

Time trends in initiation of chronic dialysis in the U.S.

Takeda, Affymax announce data from multiple studies of peginesatide on anemia

Merck receives FDA approval for JUVISYNC to treat type 2 diabetes

Health Canada approves Trajenta (linagliptin) for type 2 diabetes

Bristol-Myers to present abstracts on research in liver disease at The Liver Meeting 2011

Dialysis patients with kidney failure more likely to develop serious complications from flu

Alexion receives FDA approval for Soliris to treat atypical Hemolytic Uremic Syndrome

EMA CHMP adopts positive opinion for Soliris to treat atypical hemolytic uremic syndrome

E.U. CHMP issues positive opinion for use of Celgene's REVLIMID/dexamethasone MM drug

NYT: Ethics probe involves kidney transplant center, Rep. Berkley

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Dialysis News and Research

Latest Dialysis News and Research

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Newsletters you may be interested in